Cure My Disease

Don't miss your cure!

 Log in / Sign up

Small study aims to predict which breast cancer patients benefit from immunotherapy

NCT ID NCT05877859

Recruiting now Knowledge-focused Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is looking at how the immune system responds in people with early-stage triple negative breast cancer who receive standard chemotherapy plus the immunotherapy drug pembrolizumab before surgery. The goal is to see if certain immune markers in the blood or tumor tissue can predict whether the cancer will completely disappear after treatment. Only 10 participants will be enrolled, and the study does not test a new treatment but rather monitors responses to the current standard of care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pembrolizumab (a type of immunotherapy) given with standard chemotherapy
What this could lead to
If successful, this study could help doctors understand which patients with early-stage triple negative breast cancer are most likely to benefit from adding immunotherapy to chemotherapy before surgery.
What could go wrong
This is a very small pilot study with only 10 participants, so results may not apply to all patients. It is designed to gather information, not to prove a new treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER INVASIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm invasive breast carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER INVASIVE BREAST CANCER STAGE II BREAST CANCER STAGE III BREAST CANCER TRIPLE NEGATIVE

Contacts and locations

Locations

  • Emory University/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.